



Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 2,898 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 233,156 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Growth Strategy

With GOAL 13...

...new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

- Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
- Acquisitions of existing clinics to ensure optimized international presence
- Horizontal expansion in the sector of Renal Drugs as well as
- A boosted activity in home therapies


Key Figures - Summary Full Year 2011

Net revenue	\$ 12,795 million	+ 6%
Operating income (EBIT)	\$ 2,075 million	+ 8%
Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA	\$ 1,071 million	+ 9%
Earnings per share	\$ 3.54	+ 9%
Total assets ¹	\$ 19,533 million	
Operating cash flow ²	\$ 1,446 million	
Employees ¹	79,159	+ 8%
Patients ¹	233,156	+ 9%
Clinics ¹	2,898	+ 6%
Treatments ²	34.39 million	+ 9%

¹ as of December 31, 2011

² in the full year of 2011

Revenue full year 2011 per region (US\$ 12,795 m)



Goals for 2012

Net revenue	~ \$14.0 billion
Net income	~ \$1.14 billion
Leverage ratio (Debt/EBITDA)	< 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$1.8 billion

Management Board

- Dr. Ben J. Lipps (Chairman)
- Rice Powell (Vice Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Dr. Rainer Runte
- Kent Wanzek

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz



Share Profile – Key Data

Ticker Symbols	Ordinary shares	Preference shares
Frankfurt Stock Exchange	FME	FME3
New York Stock Exchange (NYSE)	FMS	FMS/P
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F	FMEG_p.DE / FMEG_p.F
Bloomberg	FME GY	FME3 GY
Security Identification Numbers		
WKN	578 580	578 583
ISIN	DE 0005785802	DE 0005785836
CUSIP No. (NYSE)	358029106	358029205

Financing Instruments and Maturity Profile

	Amount in million	Coupon %	Maturity
Credit Agreement Revolver	\$ 1,200		March 31, 2013
Credit Agreement Term Loan A	\$ 1,850 ¹		March 31, 2013
Credit Agreement Term Loan B	\$ 1,750 ¹		March 31, 2013
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor + 3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen)	€ 155		October 27, 2012
Notes (Schuldscheindarlehen)	€ 45		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

¹ at the beginning before amortisation and extension

Share Price Development last 12 months

in €




Financial Calendar

Event	Date
Report on Full Year 2011	
Annual Financial Report:	March 30, 2012
Report on First Quarter 2012:	May 3, 2012
Annual General Meeting:	May 10, 2012
Payment of Dividend¹:	May 11, 2012
Report on Second Quarter 2012:	August 1, 2012
Report on Third Quarter 2012:	October 31, 2012

¹ Subject to the approval of the AGM

Capital Structure

Overview



Contacts

Fresenius Medical Care AG & Co. KGaA
 Investor Relations & Corporate Communications
 Else-Kröner-Straße 1 61352 Bad Homburg
Oliver Maier P: +49(0)6172-609-2525
 Senior Vice President, F: +49(0)6172-609-2301
 Head of IR & CC
Gerrit Jost P: +49(0)6172-609-5216
 Vice President
North America
Terry L. Morris P: +1-800-948-2538
 Vice President F: +1-615-345-5605